1 |
HDAC6
| [4] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Amyotrophic lateral sclerosis, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
2 |
HDAC5
| [5] Apelin signaling pathway Apelin signaling pathway, Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis, MicroRNAs in cancer | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
3 |
CRHR1
| [4] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Long-term depression, Cushing syndrome | D03592
D03592
|
Corticorelin ovine triflutate
| [1] 75 75 |
4 |
CRHR1
| [4] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Long-term depression, Cushing syndrome | D03905
D03905
|
Corticorelin
| [2] 75 75, 205 |
5 |
CRHR2
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Cushing syndrome | D03592
D03592
|
Corticorelin ovine triflutate
| [1] 75 75 |
6 |
CRHR2
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Cushing syndrome | D03905
D03905
|
Corticorelin
| [2] 75 75, 205 |
7 |
CYP11B1
| [4] Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Cortisol synthesis and secretion, Cushing syndrome | D00410
D00410
|
Metyrapone
| [2] 75 75, 193 |
8 |
CYP11B1
| [4] Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Cortisol synthesis and secretion, Cushing syndrome | D05019
D05019
|
Metyrapone
| [2] 75 75, 193 |
9 |
CYP11B2
| [3] Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Aldosterone synthesis and secretion | D11061
D11061
|
Osilodrostat
| [1] 75 75 |
10 |
CYP17A1
| [6] Steroid hormone biosynthesis Steroid hormone biosynthesis, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Cortisol synthesis and secretion, Cushing syndrome | D00351
D00351
|
Ketoconazole
| [3] 8 8, 13, 75 |
11 |
DPP4
| [1] Protein digestion and absorption Protein digestion and absorption | D08516
D08516
|
Sitagliptin
| [3] 75 75, 233, 299 |
12 |
DRD2
| [8] Rap1 signaling pathway Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism | D00987
D00987
|
Cabergoline
| [3] 6 6, 74, 75 |
13 |
AGTR1
| [16] Calcium signaling pathway Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy | D00400
D00400
|
Valsartan
| [7] 57 57, 58, 66, 75, 218, 222, 224 |
14 |
EGFR
| [48] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D01977
D01977
|
Gefitinib
| [1] 75 75 |
15 |
EGFR
| [48] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D04024
D04024
|
Lapatinib
| [3] 34 34, 74, 75 |
16 |
EGFR
| [48] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, ErbB signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, GnRH signaling pathway, Estrogen signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Cushing syndrome, Epithelial cell signaling in Helicobacter pylori infection, Shigellosis, Hepatitis C, Human cytomegalovirus infection, Human papillomavirus infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Colorectal cancer, Pancreatic cancer, Endometrial cancer, Glioma, Prostate cancer, Melanoma, Bladder cancer, Non-small cell lung cancer, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08108
D08108
|
Lapatinib
| [3] 34 34, 74, 75 |
17 |
ERBB2
| [22] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Non-small cell lung cancer, Breast cancer, Gastric cancer, Central carbon metabolism in cancer | D04024
D04024
|
Lapatinib
| [3] 34 34, 74, 75 |
18 |
ERBB2
| [22] EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Platinum drug resistance, MAPK signaling pathway, ErbB signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, Focal adhesion, Adherens junction, Tight junction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Pancreatic cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Non-small cell lung cancer, Breast cancer, Gastric cancer, Central carbon metabolism in cancer | D08108
D08108
|
Lapatinib
| [3] 34 34, 74, 75 |
19 |
F8
| [1] Complement and coagulation cascades Complement and coagulation cascades | D00291
D00291
|
Desmopressin
| [3] 75 75, 225, 288 |
20 |
F8
| [1] Complement and coagulation cascades Complement and coagulation cascades | D02235
D02235
|
Desmopressin
| [3] 75 75, 225, 288 |
21 |
F10
| [1] Complement and coagulation cascades Complement and coagulation cascades | D07086
D07086
|
Rivaroxaban
| [3] 75 75, 91, 210 |
22 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
23 |
GABRA1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
24 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
25 |
GABRA2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
26 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
27 |
GABRA3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
28 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
29 |
GABRA4
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
30 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
31 |
GABRA5
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
32 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
33 |
GABRA6
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
34 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
35 |
GABRB1
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
36 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
37 |
GABRB2
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
38 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
39 |
GABRB3
| [6] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
40 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
41 |
GABRD
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
42 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
43 |
GABRE
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
44 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
45 |
GABRG1
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
46 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
47 |
GABRG2
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
48 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
49 |
GABRG3
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
50 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
51 |
GABRP
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
52 |
GHR
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | D02691
D02691
|
Somatotropin
| [23] 2 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299 |
53 |
GLP1R
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion | D06404
D06404
|
Liraglutide
| [3] 6 6, 75, 193 |
54 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00088
D00088
|
Hydrocortisone
| [7] 75 75, 78, 81, 83, 97, 98, 299 |
55 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00292
D00292
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
56 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00472
D00472
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
57 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00585
D00585
|
Mifepristone
| [1] 75 75 |
58 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00975
D00975
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
59 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00980
D00980
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
60 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00981
D00981
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
61 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D00982
D00982
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
62 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01239
D01239
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
63 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01510
D01510
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
64 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01615
D01615
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
65 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01632
D01632
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
66 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01948
D01948
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
67 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D01998
D01998
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
68 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02156
D02156
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
69 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02174
D02174
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
70 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02591
D02591
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
71 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D02592
D02592
|
Dexamethasone
| [13] 75 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
72 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D03301
D03301
|
Prednisolone
| [18] 75 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
73 |
NR3C1
| [1] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction | D11336
D11336
|
Relacorilant
| [1] 75 75 |
74 |
HDAC1
| [15] Cell cycle Cell cycle, Longevity regulating pathway - multiple species, Notch signaling pathway, Neutrophil extracellular trap formation, Thyroid hormone signaling pathway, Huntington disease, Amphetamine addiction, Alcoholism, Human papillomavirus infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chronic myeloid leukemia | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
75 |
HDAC2
| [15] Cell cycle Cell cycle, Longevity regulating pathway - multiple species, Notch signaling pathway, Neutrophil extracellular trap formation, Thyroid hormone signaling pathway, Huntington disease, Amphetamine addiction, Alcoholism, Human papillomavirus infection, Epstein-Barr virus infection, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chronic myeloid leukemia | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
76 |
MC2R
| [5] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome | D00146
D00146
|
Corticotropin
| [15] 2 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222 |
77 |
NR3C2
| [1] Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption | D01115
D01115
|
Eplerenone
| [4] 75 75, 113, 210, 215 |
78 |
HDAC7
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
79 |
PGR
| [5] Oocyte meiosis Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer | D00585
D00585
|
Mifepristone
| [1] 75 75 |
80 |
PML
| [7] Ubiquitin mediated proteolysis Ubiquitin mediated proteolysis, Endocytosis, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia | D00094
D00094
|
Tretinoin
| [6] 2 2, 62, 63, 75, 94, 231 |
81 |
PPARG
| [11] PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D00596
D00596
|
Rosiglitazone
| [5] 46 46, 75, 97, 222, 265 |
82 |
PPARG
| [11] PPAR signaling pathway PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis | D08491
D08491
|
Rosiglitazone
| [5] 46 46, 75, 97, 222, 265 |
83 |
AVPR2
| [3] Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D00291
D00291
|
Desmopressin
| [6] 6 6, 64, 72, 75, 225, 288 |
84 |
AVPR2
| [3] Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Vasopressin-regulated water reabsorption | D02235
D02235
|
Desmopressin
| [6] 6 6, 64, 72, 75, 225, 288 |
85 |
PRKAA1
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
86 |
PRKAA1
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
87 |
PRKAA2
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D00944
D00944
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
88 |
PRKAA2
| [20] FoxO signaling pathway FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis | D04966
D04966
|
Metformin
| [24] 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
89 |
HDAC8
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
90 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00225
D00225
|
Alprazolam
| [2] 8 8, 75 |
91 |
GABRQ
| [5] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction | D00549
D00549
|
Propofol
| [10] 6 6, 21, 22, 34, 46, 70, 75, 84, 98, 296 |
92 |
PRL
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | D00987
D00987
|
Cabergoline
| [3] 6 6, 74, 75 |
93 |
RARA
| [5] Th17 cell differentiation Th17 cell differentiation, Estrogen signaling pathway, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia | D00094
D00094
|
Tretinoin
| [6] 2 2, 62, 63, 75, 94, 231 |
94 |
RARB
| [4] Pathways in cancer Pathways in cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer | D00094
D00094
|
Tretinoin
| [6] 2 2, 62, 63, 75, 94, 231 |
95 |
RXRA
| [17] PPAR signaling pathway PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Bile secretion, Hepatitis C, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| [2] 13 13, 75 |
96 |
RXRB
| [13] PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| [2] 13 13, 75 |
97 |
RXRG
| [13] PPAR signaling pathway PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis | D03106
D03106
|
Bexarotene
| [2] 13 13, 75 |
98 |
SSTR1
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |
99 |
SSTR2
| [4] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion | D00442
D00442
|
Octreotide
| [7] 67 67, 75, 84, 85, 89, 193, 227 |
100 |
SSTR2
| [4] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion | D06495
D06495
|
Octreotide
| [7] 67 67, 75, 84, 85, 89, 193, 227 |
101 |
SSTR2
| [4] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action, Gastric acid secretion | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |
102 |
SSTR3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |
103 |
SSTR5
| [3] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action | D10147
D10147
|
Pasireotide
| [3] 67 67, 74, 75 |
104 |
VDR
| [5] Parathyroid hormone synthesis, secretion and action Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation | D00188
D00188
|
Cholecalciferol
| [25] 6 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299 |
105 |
HDAC11
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
106 |
HDAC10
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
107 |
PDE5A
| [3] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway | D02008
D02008
|
Tadalafil
| [7] 6 6, 51, 75, 84, 86, 113, 210 |
108 |
HDAC3
| [4] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Thyroid hormone signaling pathway, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
109 |
HDAC9
| [3] Neutrophil extracellular trap formation Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |
110 |
HDAC4
| [5] Apelin signaling pathway Apelin signaling pathway, Neutrophil extracellular trap formation, Alcoholism, Viral carcinogenesis, MicroRNAs in cancer | D06320
D06320
|
Vorinostat
| [3] 19 19, 75, 96 |